XOLAIR

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: 3e13c37e5afc8d75
Drug Approval Canada Name: XOLAIR
Product Name: XOLAIR
Status: Marketed
Status Date: 2017-07-06
Original Market Date: 2017-07-06
Din: 02459795
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 90:28.16.92
Atc Original: R03DX05 OMALIZUMAB
Atc Name: r 03 dx 05
Aig Number: 0150422001
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

OMALIZUMAB

150 MG / 1 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

3e13c37e5afc8d75

Type

Standard